Phosphoinositide 3-Kinase Therapy in Diabetic Cardiomyopathy: Unravelling an Enigma
Yaguang Bi,Yingmei Zhang,Jun Ren
DOI: https://doi.org/10.1152/ajpheart.00160.2020
2020-01-01
Abstract:Editorial FocusPhosphoinositide 3-kinase therapy in diabetic cardiomyopathy: unravelling an enigmaYaguang Bi, Yingmei Zhang, and Jun RenYaguang BiDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, Wyoming, Yingmei ZhangDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China, and Jun RenDepartment of Cardiology, and Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, ChinaCenter for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WyomingPublished Online:08 Apr 2020https://doi.org/10.1152/ajpheart.00160.2020This is the final version - click for previous versionMoreSectionsPDF (272 KB)Download PDFDownload PDFPlus ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmail Diabetes mellitus, the most prevalent noncommunicable epidemic threat, is expected to reach an astonishing 600 million by year 2035 (1). Cardiovascular anomalies are commonly seen in diabetes, contributing to the high morbidity and mortality in patients with diabetes (5, 9, 11). In particular, undesired geometric and functional changes develop in diabetic hearts, independent of any macro- and microvascular comorbidities, leading to pronounced cardiac remodeling, systolic and diastolic dysfunction, including compromised myocardial contractile capacity, and prolonged duration and reduced velocity of contraction and relaxation, a condition commonly known as diabetic cardiomyopathy, first described by Rubler and colleagues in 1972 (5, 9, 11). Clinical observations using electrocardiogram and echocardiography have unveiled substantial changes in diabetic human hearts including altered left ventricular ejection time, preejection duration, left ventricular filling time, action potential duration, ventricular wall stiffness, and ejection fraction (5, 9, 11). Ample cellular and molecular mechanisms have been postulated for the pathogenesis of diabetic cardiomyopathy, encompassing mitochondrial injury, oxidative stress, inflammation, apoptosis, autophagy failure, disturbed energy metabolism, and intracellular Ca2+ defect (5, 9). Preclinical evidence over the past decades has also indicated a cadre of cell signaling therapeutic targets and strategies, such as antioxidative [nuclear factor erythroid 2-like 2 (Nrf2) activators, curcumin products, vitamins, and metallothionein derivatives], antifibrotic (melatonin, resveratrol, relaxin, and phosphodiesterase 5 inhibitors), anti-inflammatory [luteolin, Klotho, ursolic acid, epigallocatechin-3-gallate, statins, Toll-like receptor 4 (TLR4) inhibitors, NOD-like receptor family pyrin domain containing 3 (NLRP3) inhibitors, and tumor necrosis factor-α (TNF-α) inhibitors] and antiapoptotic (Fisetin, hydrogen sulfide, and lipid lowering statins) agents (5, 9, 11). Many of these interventions involve multiple therapeutic benefits such as concurrent antioxidation and anti-inflammation. Nonetheless, subsequent clinical trials for these therapeutic maneuvers, although somewhat promising for initial results (9), remain to be fully validated. Much more work is still warranted to better understand the pathogenesis of such myopathic condition in patients with diabetes and in particular type 2 diabetes (T2D), which is much more prevalent in comparison with type 1 diabetic (T1D) populations.In a recent issue of the American Journal of Physiology-Heart and Circulatory Physiology, Prakoso and colleagues (8) reported that administration of recombinant adeno-associated viral vectors carrying a constitutively active phosphoinositide 3-kinase [PI3K (p110α)] construct (rAAV6-caPI3K) effectively ameliorated diabetic cardiac remodeling and contractile dysfunction in a T2D model using a combination of high-fat diet (42% energy intake from fat) and streptozotocin (3 consecutive 55 mg/kg body wt ip). These authors noted evident cardiac anomalies in this preclinical T2D model as manifested by impaired left ventricular systolic function (fractional shortening and velocity of circumferential fiber shortening) and unfavorable cardiac remodeling (hypertrophy and interstitial and perivascular collagen deposition). Strikingly, T2D-induced cardiac dysfunction and remodeling were effectively rescued by a single delivery of cardiac targeted rAAV6-caPI3K. Mechanistically, these authors revealed decreased levels of reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress in response to the cardiac-selective rAAV6-caPI3K delivery (Fig. 1), which seems to underscore functional and geometric benefits from PI3K (p110α) gene therapy (8). Earlier finding from this group reported that the very same cardiac rAAV6-caPI3K (p110α) gene delivery greatly limits cardiac remodeling, contractile dysfunction, ER stress, and apoptosis in streptozotocin (5 consecutive 55 mg/kg body wt ip)-induced T1D model, possibly through regulation of NADPH oxidase (7). It is noteworthy that rAAV6-caPI3K was delivered following the establishment of diabetic cardiomyopathy phenotype in both T2D and T1D models (7, 8), mimicking a clinically relevant situation. These findings collectively denote an important role for PI3K in the novel therapeutics against diabetic cardiomyopathy.Fig. 1.Schematic diagram depicting possible mechanism(s) of involved in phosphoinositide 3-kinase (PI3K)α-induced beneficial effects against diabetes-induced anomalies in cardiac contractile function, morphology, and cell survival. PI3Kα (p110α) inhibits endoplasmic reticulum (ER) stress and oxidative stress to counteract diabetic insult to the heart. rAAV6-caPI3K, recombinant adeno-associated viral vectors carrying a constitutively active PI3K (p110α) construct; ROS, reactive oxygen species.Download figureDownload PowerPointPI3Ks belong to a large family of heterodimer lipid/protein kinases that serve as a central regulator for both physiological and pathophysiological processes, including cell growth and cell survival (2, 6). PI3Ks (class I) comprise a catalytic subunit (p110α, p110β, or p110δ), which is bound to the regulatory subunits (p85 and p55). Ample findings have depicted a rather important role for the p110α subunit along with its downstream signaling molecule Akt in the regulation of insulin signaling and metabolic profiles in particular in the etiology of insulin resistance, obesity, and diabetes mellitus (2–4, 6). PI3Kα ablation is embryonically lethal, whereas adipose PI3K (p110α) deletion results in overt adiposity and body weight gain (2). Likewise, the kinase-dead knock-in allele of p110α of PI3K displays hyperinsulinemia and impaired glucose tolerance, a phenotype reminiscent of those seen with deficiency in p85 regulatory subunit of PI3K. Mice with diminished cardiac PI3K (p110α) activity elicited by a dominant negative (dn) PI3K (p110α) mutant or deletion of p85 subunits exhibited cardiac atrophy at basal condition and dampened hypertrophic response upon exercise. To the contrary, transgenic mice with a constitutively active PI3K (p110α) mutant exhibited physiological cardiac hypertrophy under basal conditions and improved cardiac function or lifespan in stress conditions such as myocardial infarction or dilated cardiomyopathy (10). With genetically engineered mouse models, both beneficial and detrimental roles for PI3Kα have been noted in cardiovascular pathophysiological processes (2). In this context, governance of PI3K signaling, in particular p110α, is cardinal to the regulation of systemic glucose and lipid metabolism. However, limited availability of PI3K activators along with pharmacokinetic shortfalls such as poor bioavailability and fast metabolism, chemical instability, and safety/toxicity concerns have largely limited the clinical application of PI3K activators. Moreover, overstimulation of PI3K and its downstream signaling molecule Akt has been demonstrated to trigger cardiac hypertrophy and is deemed detrimental in certain conditions such as aging (4). To this end, the hunt for more specific or tissue-selective PI3K modulators may represent a novel approach in pharmacotherapy for the management of diabetes and diabetic complications. Although this study from Prakoso and colleagues (8) has unveiled the therapeutic potential of PI3K activation in the treatment and management of diabetic cardiomyopathy, more questions remain to be answered. First, can PI3K analog be employed for dyslipidemia and obesity-induced cardiovascular anomalies, and if so, what is the mechanism(s) of action behind PI3K (p110α)-elicited benefit against obesity-induced cardiovascular dysfunction? Given the well-established role of PI3K in insulin signaling and lipid metabolism (2) and close association between obesity and T2D (11), possible added benefit (or risk) of PI3K-targeted therapy in obese T2D should be weighed. Second, it was reported that loss of PI3Kα using genetically engineered mice failed to reveal any inherently pathological changes to the heart in otherwise healthy mice (6), somewhat inconsistent with those reported in mice overexpressing a dnPI3K (p110α) mutant or with deletion of p85 subunits (10). Thus, the onset and development of diabetic cardiomyopathy is unlikely originated from defects in PI3Kα itself. What is the precise role of PI3Kα in the pathogenesis of diabetic cardiomyopathy? Are there any other confounding factors to launch the “diabetic cardiomyopathy missile” in the presence of PI3K abnormality? At this time, proper clinical management for diabetic cardiomyopathy mainly encompasses proper control of glucose and lipid metabolism, correction of coronary artery diseases, hypertension and inflammation, along with nonpharmacotherapies such as lifestyle modification and exercise. Many of these measures should help to harness the PI3K signaling (such as exercise training), although the precise mechanism(s) of action remains elusive. Last but not the least, improper or chronic activation of PI3K-Akt signaling cascade may bring significant clinical concerns such as cancer prevalence, thus pharmacological therapies targeting PI3K may have to be handled with special caution under certain clinical scenarios.GRANTSThis work was supported in part by National Science Foundation Grant NSF-81770261.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSY.B., Y.Z., and J.R. drafted, edited, and revised manuscript.REFERENCES1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137–149, 2014. doi:10.1016/j.diabres.2013.11.002. Crossref | PubMed | ISI | Google Scholar2. Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020 March 3. [Epub ahead of print.] 2020. doi:10.1038/s41574-020-0329-9. Crossref | PubMed | ISI | Google Scholar3. Hu N, Ren J, Zhang Y. Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α. Oncotarget 7: 76398–76414, 2016. doi:10.18632/oncotarget.11977. Crossref | PubMed | Google Scholar4. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 106: 1173–1191, 2011. doi:10.1007/s00395-011-0222-8. Crossref | PubMed | ISI | Google Scholar5. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122: 624–638, 2018. doi:10.1161/CIRCRESAHA.117.311586. Crossref | PubMed | ISI | Google Scholar6. McLean BA, Zhabyeyev P, Patel VB, Basu R, Parajuli N, DesAulniers J, Murray AG, Kassiri Z, Vanhaesebroeck B, Oudit GY. PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovasc Res 105: 292–303, 2015. doi:10.1093/cvr/cvv016. Crossref | PubMed | ISI | Google Scholar7. Prakoso D, De Blasio MJ, Qin C, Rosli S, Kiriazis H, Qian H, Du XJ, Weeks KL, Gregorevic P, McMullen JR, Ritchie RH. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond) 131: 1345–1360, 2017. doi:10.1042/CS20170063. Crossref | PubMed | ISI | Google Scholar8. Prakoso D, De Blasio MJ, Tate M, Kiriazis H, Donner DG, Qian H, Nash D, Deo M, Weeks KL, Parry LJ, Gregorevic P, McMullen JR, Ritchie RH. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol Heart Circ Physiol 318: H840–H852, 2020. doi:10.1152/ajpheart.00632.2019. Link | ISI | Google Scholar9. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020 February 20. [Epub ahead of print.] doi:10.1038/s41569-020-0339-2. Crossref | PubMed | ISI | Google Scholar10. Weeks KL, Gao X, Du XJ, Boey EJ, Matsumoto A, Bernardo BC, Kiriazis H, Cemerlang N, Tan JW, Tham YK, Franke TF, Qian H, Bogoyevitch MA, Woodcock EA, Febbraio MA, Gregorevic P, McMullen JR. Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5: 523–534, 2012. doi:10.1161/CIRCHEARTFAILURE.112.966622. Crossref | PubMed | ISI | Google Scholar11. Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther 191: 1–22, 2018. doi:10.1016/j.pharmthera.2018.06.004. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for correspondence: J. Ren, Univ. of Wyoming College of Health Sciences, 1000 E. University Ave., Dept. 3375, Laramie, WY 82071 (e-mail: [email protected]edu). Previous Back to Top Next FiguresReferencesRelatedInformationRelated articlesGene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes 24 Mar 2020American Journal of Physiology-Heart and Circulatory PhysiologyCited ByHyperglycemic memory in diabetic cardiomyopathy18 December 2021 | Frontiers of Medicine, Vol. 25Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy via FAK/SIRT3/ROS Pathway in Cardiomyocyte20 September 2021 | Frontiers in Endocrinology, Vol. 12Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy22 July 2021 | Frontiers in Endocrinology, Vol. 12Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathyBiomedicine & Pharmacotherapy, Vol. 128Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway19 May 2020 | Frontiers in Physiology, Vol. 11 More from this issue > Volume 318Issue 5May 2020Pages H1029-H1031 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajpheart.00160.2020PubMed32167783History Received 9 March 2020 Accepted 11 March 2020 Published online 8 April 2020 Published in print 1 May 2020 Metrics Downloaded 286 times